Amneal Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net income (loss) | $35,610 | $16,787 | $60,228 | $(64,891) |
| Less: Net income attributable to non-controlling interests | (13,193) | (10,793) | (25,616) | (20,758) |
| Net income (loss) attributable to Amneal Pharmaceuticals, Inc. | 22,417 | 5,994 | 34,612 | (85,649) |
| Other comprehensive (loss) income: | ||||
| Foreign currency translation adjustments arising during the period | (4,928) | (39) | (6,560) | (429) |
| Unrealized (loss) gain on cash flow hedge, net of tax of $0 | (7,331) | (170) | (19,485) | 15,373 |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | 568 | (6,516) | (5,876) | (13,031) |
| Other comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. | (11,691) | (6,725) | (31,921) | 1,913 |
| Comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. | $10,726 | $(731) | $2,691 | $(83,736) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.